Biomerica vs ImmuCell
BMRA and ICCC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BMRA and ICCC compare
ImmuCell is the larger company, worth 16 times as much as Biomerica ($92.8M against $6.0M).
ImmuCell grew revenue faster over the last twelve months (19.6% versus −11.2% for Biomerica).
ImmuCell keeps more of each dollar of sales as profit, with a net margin of 5.7% compared with −115% at Biomerica.
ImmuCell scores higher on the StockData Score (12 against 8 for Biomerica), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BMRA | ICCC |
|---|---|---|
| Size and price | ||
| Market cap | $6.0M | $92.8M |
| Share price | $1.30 | $10.22 |
| Change, 1 year | −48.6% | 63.0% |
| Change, 5 years | −96.8% | 15.6% |
| Beta (5Y) | 0.94 | 0.10 |
| Employees | 17 | 73 |
| StockData Score | ||
| Total score | 8 | 12 (better) |
| Valuation score | 3 (better) | 1 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 51.1× |
| P/S | 1.4× (better) | 2.8× |
| P/B | 1.6× (better) | 2.8× |
| EV/EBITDA | – | 13.3× |
| P/FCF | – | 17.2× |
| FCF yield | – | 5.8% |
| Fair value | $2.39 | $8.80 |
| Margin of safety | 45.6% (better) | −16.1% |
| Growth | ||
| Revenue growth (TTM) | −11.2% | 19.6% (better) |
| Revenue growth, 5Y average | −9.2% | 12.5% (better) |
| Net income growth (TTM) | – | −19.1% |
| EPS growth (TTM) | – | −23.1% |
| Profitability | ||
| Gross margin | 0.90% | 40.8% (better) |
| Operating margin | −125% | 14.5% (better) |
| Net margin | −115% | 5.7% (better) |
| FCF margin | – | 16.3% |
| Return on equity | −114% | 6.0% (better) |
| Return on invested capital | −284% | 13.8% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.24 (better) |
| Net debt / EBITDA | – | −0.00 |
| Interest coverage | – | 12.2× |
| Current ratio | 1.91 | 4.61 (better) |
| Altman Z-score | −10.58 | 4.81 (better) |
| Piotroski F-score | 4 | 7 (better) |
| Dividends and buybacks | ||
| Buyback yield | −53.0% | 0.00% (better) |
| Shareholder yield | −53.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 2.7% | 14.7% |
| Held by insiders | 27.4% | 13.6% |
| Insider net buying, 12 months | $158K (better) | $156K |
| Short interest, % of float | 0.37% | 0.19% |
Go deeper
- BMRA stock overview
- BMRA income statement
- BMRA valuation and score
- ICCC stock overview
- ICCC income statement
- ICCC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.